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http://dx.doi.org/10.1016/j.fjs.2012.Summary Radiotherapy and radiosurgery are important modes of treatment for benign and
malignant brain tumors. Radiation-induced tumors and radiation-induced malignant transfor-
mation of tumors have been described in many reports. Radiotherapy is one of the standard
treatments for intracranial glial tumors. However, there is limited discussion of radiation carci-
nogenesis in glioma treatment. We present a 58-year-old male who was initially diagnosed to
have low-grade glioma in an eloquent area of the brain by stereotactic biopsy. The tumor pro-
gressed rapidly after radiotherapy and a second stereotactic biopsy was done. Based on the
WHO classification, the diagnosis for the second specimen was high-grade glioma. Histopa-
thology showed that the expression of TP53 had increased from 40% to 60% in the second spec-
imen. The finding was consistent with other reports of the malignant transformation of benign
tumor after radiotherapy. Radiation carcinogenesis may be one of the causes for tumor
progression to high-grade within 6 months. The effect of radiotherapy on the control of glioma
is well-documented. Radiation carcinogenesis, which could cause malignant transformation of
benign brain tumors, could also be observed in low-grade glioma. This report clearly indicates
that caution is warranted regarding the use of radiotherapy for glial tumors, especially for low-
grade gliomas.
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20 Y.-C. Hung et al.1. Introduction temozolomidel as a secondary treatment, and alsoGlioma is the most common intracranial neoplasm in
humans. According to the EORTC 22845 randomized trial,1
the median overall survival of patients with low-grade
gliomas after microsurgery was around 7 years. Although
debulking surgery is the treatment of choice, for patients
with tumors located in the eloquent or near-eloquent
areas, stereotactic biopsy followed by adjuvant radio-
therapy with chemotherapy is one of the options for
treatment.2 Considering the benefit and possible adverse
effect of radiotherapy, such as radiation leukoencephal-
opathy, low-grade astrocytoma could be observed only in
low-risk patients, and radiotherapy is considered in high-
risk patients if the disease has already progressed to
some extent.3 In patients with low-grade glioma who
received early radiotherapy, the median progression-free
survival was longer, but the overall survival was similar to
that of the control group.1
We present a case with the initial histopathological
diagnosis of low-grade astrocytoma after undergoing
stereotactic biopsy. Radiology revealed that the tumor
progressed soon after the whole brain radiotherapy was
completed. High-grade glioma was diagnosed by specimens
of the second stereotactic biopsy and a follow-up crani-
otomy 6 months and 8 months later, respectively. In this
report, we discuss the histopathological changes seen in the
three surgical specimens and try to give possible explana-
tions for his rapid clinical deterioration.
2. Case report
A 58-year-old male presented to the emergency room with
sudden-onset aphasia. Neurological examination showed no
significant focal neurological deficits other than aphasia.
Brain magnetic resonance imaging (MRI) showed a non-
enhanced brain tumor in the left frontoparietal lobe
(Fig. 1). The patient then underwent stereotactic biopsy for
diagnosis. The histopathological report of the specimen was
astrocytoma [World Health Organization (WHO) Grade II,
Fig. 2, Table 1]. Debulking surgery under intraoperative
monitoring was suggested, but the patient refused. We
then arranged radiotherapy (60 Gy to the tumor bed and
54 Gy to the subclinical regions) as primary treatment. The
follow-up brain MRI 3 months after the first biopsy showed
a slight increase in the T2 high signal lesion in the left
frontoparietal lobe, without significant tumor progression
(Fig. 1).
Headache, right-hand weakness, dysarthria, and inter-
mittent aphasia developed 6 months after the first biopsy.
The follow-up brain MRI showed an increase in tumor size
on T2-weighted images, and a newly formed ring-
enhanced area in the center of the tumor was noted on
T1WI, without midline structure shifting (Fig. 1). The
patient then underwent a second stereotactic biopsy on
account of a suspicion of tumor progression, based on
imaging findings. The second pathology report confirmed
the diagnosis of the tumor as an anaplastic astrocytoma,
with increased expression of TP53 and O-6-methylguanine-
DNA methyltransferase (MGMT; WHO Grade III, Fig. 2,
Table 1). We then administered chemotherapy witharranged concomitant radiotherapy (50 Gy for the tumor
bed and 25 Gy in the subclinical regions).
However, symptoms of right-side limb weakness and
dysarthria progressed 2 months after the second treatment.
His follow-up brain MRI showed a progressive marginally
enhanced lesion in the left temporo-parietal lobe with
severe perifocal edema (Fig. 1). The differential diagnoses
included radiation necrosis due to large dosage of radio-
therapy and tumor progression. Because of the remarkable
mass effect, craniotomy for tumor removal was performed.
The pathology report of the specimen obtained in this
operation revealed the diagnosis had changed to glioblas-
toma multiforme by the presence of pseudopalisading
necrosis (WHO Grade IV, Fig. 2, Table 1). The patient did
not respond well to temozolomide chemotherapy after
craniotomy, and the disease continued to progress. He was
kept under supportive hospice care, and died 18 months
after the initial diagnosis.3. Discussion
Carcinogenesis due to radiotherapy in the treatment of
benign brain tumor has been documented in many reports.
Nishio et al reported 11 patients who underwent cranial
irradiation and developed secondary tumors within a span
of 13 years.4 Another possible effect of radiotherapy is
radiation-induced malignant transformation of tumors,
which can occur after radiation treatment for benign
tumors, such as vestibular schwannoma5 and pituitary
adenoma.6 The possible mechanism is that an insufficient
number of cells are killed in the tumor and some of the
surviving cells acquire mutations in genes, such as TP53,
that can transform a benign tumor into a malignant one.7 In
our case, the TP53 gene mutation rate increased from 40%
in the first specimen to 60% in the second after treatment
(Fig. 2). This was molecular biological evidence that the
tumor in our patient showed a similar transformation
process as malignant transformation in benign tumor after
radiotherapy.5e7
According to the literature, there are two subtypes of
glioblastoma: primary (de novo) and secondary. Secondary
glioblastomas (5% of glioblastoma patients) develop
through progression from low-grade diffuse astrocytoma or
anaplastic astrocytoma. The specimens of secondary glio-
blastomas were characterized by frequent LOH 10q (63%)
and TP53 mutations.8 In our patient, the histopathological
diagnosis of astrocytoma in the first specimen and the
expression of TP53 mutation in the glioblastoma specimen
were consistent with the diagnosis of secondary glioblas-
toma, which implied that the tumor had developed from
a lower grade tumor.
MGMT promoter methylation is an important prognostic
factor for glioma. Patients with methylated-MGMT tumors
had a greater chance of responding to adjuvant therapy and
a more favorable clinical outcome.9 In the second specimen
of our case, the unmethylated-MGMT increased from 50% to
70%; the MIB-1 index from 1% to 15%; and there was
a presence of cell mitosis (Fig. 2). These findings might
imply the resultant “malignant transformation”, or dedif-
ferentiation after TP53 mutation.
Figure 1 Serial brain MRI showed the rapid progression of the tumor within 9 months. (A) Upper row: Transaxial T2-weighted
images show tumor growth with progressively increasing perifocal edema around the tumor. Anterior to the lesion, a focal
stable signal abnormality is depicted. Middle row: transaxial contrast-enhanced T1-weighted images demonstrate tumor
progression with a growing central necrotic area of the tumor. Lower row: diffusion-weighted images (DWI) show initially
heterogeneous signals with a high signal rim at the periphery; the anterior portion of the tumor had transferred to high signals on
DWI at the last imaging study. (B) The target of the first stereotactic biopsy was set at the geographic center of the lesion. (C) The
target of the second stereotactic biopsy was set at the enhancing part of the tumor, which also showed high signals on DWI.
Figure 2 (A) Astrocytoma World Health Organization (WHO) Grade II with hypercellularity and nuclear pleomorphism [first
biopsy, hematoxylin and eosin (H&E) stain, original magnification 200]. (B) Anaplastic astrocytoma WHO Grade III showing
increased of mitotic activity (second biopsy, H&E stain, original magnification 200). (C) Glioblastoma WHO Grade IV with pseu-
dopalisading necrosis (craniotomy, H&E stain, original magnification 200). (D) About 40% of neoplastic astrocytes are immuno-
reactive for P53 (first biopsy, anti-P53 protein, original magnification 400, positive staining in pink). (E) Around 60% of neoplastic
astrocytes are immunoreactive for P53 (second biopsy, anti-P53 protein, original magnification 400).
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Table 1 The presence of immunostaining in different histological specimens.
Operation First stereotactic biopsy Second stereotactic biopsy
(6 months after first biopsy)
Craniotomy (2 months
after second biopsy)
Histopathological diagnosis Astrocytoma
(Grade II)
Anaplastic astrocytoma
(Grade III)
Glioblastoma
(Grade IV)
Immunostaining
P53 40% 60% 60%
MIB-1 (Ki-67) 1% 15% N/A
MGMT 50% 70%, 2þ 70%, 2þ
22 Y.-C. Hung et al.In the current literature, there is no report comparing
the histopathological and immunostaining findings of
glioma before and after radiotherapy to prove the
possible dedifferentiation of glioma after radiation.
However, several previous reports have mentioned that
this radiation adverse effect may occur in other benign
brain tumors.5,6 Further studies are needed to clarify the
definitive mechanism of radiation carcinogenesis in glial
tumors.
In conclusion, the role of radiotherapy in genetic and
histopathological change is still unclear. Radiation carci-
nogenesis is possible, as seen in the treatment of benign
brain tumors. However, more scientific evidence is needed
to establish the definitive mechanism. In the treatment of
glial tumor, caution is indispensable with regard to the use
of radiotherapy, especially for low-grade gliomas. For
younger patients without focal deficits, a “wait and see”
policy, or withholding radiotherapy until clinical or radio-
logical tumor progression, could be a better option.Acknowledgments
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